Navigation Links
New Shire Holding Company Proposal
Date:4/16/2008

BASINGSTOKE, England and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- Shire plc ("Shire" or the "Company") (LSE: SHP) (NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that further to yesterday's announcement regarding Shire's new holding company proposal, it will today post the Circular and associated documents to its shareholders. A Prospectus, in relation to the ordinary shares in the new Shire holding company, to be called Shire Limited, has been published and both the Prospectus and Circular have been posted on the Company's website: http://www.shire.com.

Copies of the Circular and Prospectus have been submitted to the UK Listing Authority and are available for inspection at the Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS, tel. +44-20-7066-1000.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire to Introduce a New UK Listed Holding Company
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Shire plc: Long Term Incentive Plan
4. Shire plc: IFRS Results for the Year Ending December 31, 2007
5. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
6. Shire plc: Correction Re Website
7. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
8. Shire Engages Palio
9. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... and commercializes proprietary technologies and products for advanced microarray ... the fiscal first quarter ended December  31, 2014. All ... (CAD), unless otherwise stated. "During the ... our existing customers and add to our sales pipeline," ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
(Date:2/26/2015)... BioEnterprise today announced that Northeast ... $2 billion in growth funding during the past 13 ... sources, state – including the Ohio Third Frontier - ... has been raised in the past five years. ... the BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... SAN DIEGO, June 1, 2011 Tioga Pharmaceuticals, Inc. ... granted Fast Track designation by the U.S. Food and ... diarrhea-predominant irritable bowel syndrome (D-IBS). Tioga is conducting a ... conducted under a Special Protocol Assessment agreement with the ...
... 2011 Reportlinker.com announces that a new ... catalogue: Osteosarcoma Therapeutics - ... http://www.reportlinker.com/p0546797/Osteosarcoma-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... Market Forecasts to 2017 ...
... a new quasiparticle called the "hybrid plasmon polariton" ... circuits and optical computing for the 21st century. ... Lawrence Berkeley National Laboratory (Berkeley Lab) have demonstrated ... on-chip optical communication systems. "We have ...
Cached Biology Technology:FDA Grants Fast Track Designation to Tioga Pharmaceuticals' Asimadoline for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 9Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017 10Nanoscale waveguide for future photonics 2Nanoscale waveguide for future photonics 3Nanoscale waveguide for future photonics 4
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... mellifera) to the Americas, Mayan bee keepers harvested honey from ... Now, colleagues from the Colegio de la Frontera Sur in ... warn of the imminent demise of stingless bee keeping on ... loss. , "In our initial surveys of bee keepers working ...
... for drug resistance in HIV-infected patients at the time ... life expectancy, according to an article in the Nov. ... , Resistance to antiretroviral therapy, even in patients ... However, genotype resistance testing, which involves looking for the ...
... Covering ship hulls with artificial shark skin could help ... as barnacles on ship hulls is a major cause ... skin offers a structural design that prevents this so ... Applied Sciences, Bremen, Germany, is presenting his work on ...
Cached Biology News:Mayan stingless bee keeping: Going, going, gone? 2Drug resistance testing in treatment-naive HIV patients is cost-effective 2
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
...
... PRKAR2 cAMP is a signaling molecule ... cAMP exerts its effects by activating the ... signal through phosphorylation of different target proteins. ... tetramer composed of two regulatory and two ...
...
Biology Products: